封面
市场调查报告书
商品编码
1532642

减肥和肥胖管理市场规模- 产品和服务(补充剂、药物[GLP-1 受体激动剂、脂肪酶抑製剂、血清素受体激动剂]、设备[健身监测、外科]、服务)、年龄组与全球预测,2024 年- 2032 年

Weight Loss and Obesity Management Market Size - Product and Services (Supplement, Drug [GLP-1 Receptor Agonist, Lipase Inhibitor, Serotonin Receptor Agonist], Equipment [Fitness Monitoring, Surgical], Service), Age Group & Global Forecast, 2024 - 2032

出版日期: | 出版商: Global Market Insights Inc. | 英文 86 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于人们对肥胖相关健康风险(如糖尿病、心血管问题和高血压)的认识不断提高,减肥和肥胖管理市场在 2024 年和 2032 年的复合年增长率将超过 8.6%。据世界卫生组织 (WHO) 称,到 2022 年,将有超过 6.5 亿成年人肥胖,凸显了采取有效干预措施的紧迫性。与此同时,久坐生活方式和不良饮食习惯的激增正在加剧肥胖率。多样化的减肥计划、膳食补充剂和健身器材的出现,满足了追求有效体重管理和改善健康的个人的需求,将有利于市场前景。

微创手术和创新健身设备等技术进步正在提升产业份额。人们越来越多地采用数位健康平台和行动应用程式来进行个人化体重管理和即时追踪。例如,美国心臟协会的一份报告强调,数位健康干预措施可以平均减轻 3.5% 的体重。全球范围内旨在控制肥胖率和促进更健康生活的政府措施将推动需求。

整个减重和肥胖管理市场根据产品和服务、年龄层和地区进行分类。

由于人们越来越意识到体力活动对于维持健康体重的重要性,设备领域正在受到巨大的关注。随着越来越多的人采用以健身为中心的生活方式,由于便利性和可及性,人们更喜欢家庭健身器材。此外,健身技术的进步,例如提供即时追踪和个人化运动计画的智慧健身机和可穿戴设备,使这些产品对寻求有效且有吸引力的体重管理方法的消费者更具吸引力。

由于儿童肥胖症盛行率不断上升,儿童肥胖症已成为全球主要的公共卫生问题,因此儿童市场在预测期内将显着成长。家长和教育工作者对与儿童肥胖相关的长期健康风险的认识不断提高,推动了针对年轻群体量身定制的专门体重管理计划和产品的需求。此外,旨在促进儿童体育活动和健康饮食习惯的政府倡议和学校计划预计将促进该细分市场的成长。

由于肥胖症(尤其是儿童肥胖症)盛行率不断上升,到 2032 年,欧洲减肥和肥胖管理行业的复合年增长率将强劲。肥胖率的上升与久坐的生活方式、不健康的饮食习惯和高热量食物的消费增加有关。此外,人们越来越认识并采用体重管理计划和手术干预措施,这得到了旨在促进更健康生活方式的政府倡议的进一步支持。随着消费者寻求更安全、更有效的减肥解决方案,天然和有机体重管理补充剂的日益普及也促进了行业的成长

目录

第 1 章:方法与范围

第 2 章:执行摘要

第 3 章:产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 肥胖和超重的盛行率不断增加
      • 肥胖治疗药物的批准不断增加
      • 提高全民健身意识
      • 对治疗极度肥胖的减重手术的需求不断增长
    • 产业陷阱与挑战
      • 不良事件发生率增加
      • 营养保健品缺乏标准化
  • 成长潜力分析
  • 未来市场趋势
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章:竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章:市场估计与预测:按产品和服务划分,2021 - 2032 年

  • 主要趋势
  • 补充品
  • 药品
    • GLP-1受体激动剂
    • 脂肪酶抑制剂
    • 组合药物
    • 血清素受体激动剂
    • 其他药品
  • 装置
    • 健身器材
    • 健身监测设备
    • 手术设备
    • 其他设备
  • 服务

第 6 章:市场估计与预测:按年龄划分,2021 - 2032

  • 主要趋势
  • 成人
  • 孩子们

第 7 章:市场估计与预测:按地区,2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 8 章:公司简介

  • Allurion
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Equinox Inc.
  • FOUND
  • Herbalife International of America, Inc.
  • Johnson & Johnson Services Inc. (Ethicon Inc.)
  • Kellogg Co.
  • Lifetime Fitness Inc.
  • Medtronic plc
  • Novo Nordisk A/S
  • Nutrisystem, Inc.
  • OptiBiotix Online
  • PRISTYN CARE
  • Roman Health Ventures Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Teleflex Inc.
  • VIVUS LLC.
  • WW International, Inc.
简介目录
Product Code: 9706

The Weight Loss and Obesity Management Market will register over 8.6% CAGR over 2024 and 2032, driven by the heightened awareness of the health risks linked to obesity, such as diabetes, cardiovascular issues, and hypertension. According to the World Health Organization (WHO), over 650 million adults were obese in 2022, underscoring the urgency for effective interventions. Concurrently, a surge in sedentary lifestyles and poor dietary habits is amplifying obesity rates. The availability of diverse weight loss programs, dietary supplements, and fitness equipment, catering to individuals striving for effective weight management and better health will favor the market outlook.

Technological strides, like minimally invasive surgeries and innovative fitness devices, are bolstering industry share. There is increasing adoption of digital health platforms and mobile apps for personalized weight management and real-time tracking. For instance, a report by the American Heart Association highlighted that digital health interventions could reduce body weight by an average of 3.5%. The government initiatives worldwide, aimed at curbing obesity rates and promoting healthier living, will push the demand.

The overall weight loss and obesity management market is classified based on product & services, age group, and region.

The equipment segment is witnessing significant traction due to the rising awareness of the importance of physical activity in maintaining a healthy weight. As more individuals adopt fitness-centric lifestyles, there is a preference for home-based exercise equipment, driven by convenience and accessibility. Additionally, advancements in fitness technology, such as smart exercise machines and wearable devices that offer real-time tracking and personalized workout plans, are making these products more appealing to consumers seeking effective and engaging ways to manage their weight.

The children segment is poised to display significant growth over the forecast period, owing to the rising prevalence of childhood obesity, which has become a major public health concern globally. Increasing awareness among parents and educators about the long-term health risks associated with obesity in children is driving demand for specialized weight management programs and products tailored to younger age groups. Furthermore, government initiatives and school-based programs aimed at promoting physical activity and healthy eating habits among children are expected to bolster the segment growth.

Europe weight loss and obesity management industry will register strong CAGR through 2032, driven by the increasing prevalence of obesity, especially among children. This rise in obesity rates is linked to sedentary lifestyles, unhealthy eating habits, and increased consumption of high-calorie foods. Additionally, there is a growing awareness and adoption of weight management programs and surgical interventions, which are further supported by government initiatives aimed at promoting healthier lifestyles. The rising popularity of natural and organic weight management supplements also contributes to the industry growth, as consumers seek safer and more effective solutions for weight loss

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of obesity and overweight
      • 3.2.1.2 Growing approval for obesity treatment drugs
      • 3.2.1.3 Increasing awareness towards fitness activities
      • 3.2.1.4 Growing demand for bariatric surgery to treat extreme obesity
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Increasing incidence of adverse events
      • 3.2.2.2 Lack of standardization in nutraceuticals
  • 3.3 Growth potential analysis
  • 3.4 Future market trends
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product & Services, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Supplements
  • 5.3 Drugs
    • 5.3.1 GLP-1 receptor agonists
    • 5.3.2 Lipase inhibitors
    • 5.3.3 Combination drugs
    • 5.3.4 Serotonin receptor agonists
    • 5.3.5 Other drugs
  • 5.4 Equipment
    • 5.4.1 Fitness equipment
    • 5.4.2 Fitness monitoring equipment
    • 5.4.3 Surgical equipment
    • 5.4.4 Other equipment
  • 5.5 Services

Chapter 6 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Adult
  • 6.3 Children

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
    • 7.3.7 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Allurion
  • 8.2 Amgen Inc.
  • 8.3 Boehringer Ingelheim International GmbH
  • 8.4 Eisai Co., Ltd.
  • 8.5 Equinox Inc.
  • 8.6 FOUND
  • 8.7 Herbalife International of America, Inc.
  • 8.8 Johnson & Johnson Services Inc. (Ethicon Inc.)
  • 8.9 Kellogg Co.
  • 8.10 Lifetime Fitness Inc.
  • 8.11 Medtronic plc
  • 8.12 Novo Nordisk A/S
  • 8.13 Nutrisystem, Inc.
  • 8.14 OptiBiotix Online
  • 8.15 PRISTYN CARE
  • 8.16 Roman Health Ventures Inc.
  • 8.17 Takeda Pharmaceutical Company Ltd.
  • 8.18 Teleflex Inc.
  • 8.19 VIVUS LLC.
  • 8.20 WW International, Inc.